719
vs
H
Hang Seng (Hong Kong)
719
Over the past 12 months, Shandong Xinhua Pharmaceutical Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +16% compared to the Hang Seng (Hong Kong)'s +4% growth.
Stocks Performance
719 vs Hang Seng (Hong Kong)
Performance Gap
719 vs Hang Seng (Hong Kong)
Performance By Year
719 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shandong Xinhua Pharmaceutical Co Ltd
Glance View
In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.
